Evidence map›Paper›PMID 27355323›Full record

ArticlePloS one2016

Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort.

Joseph S Doyle, Jason Grebely, Tim Spelman, Maryam Alavi, Gail V Matthews, Alexander J Thompson, Gregory J Dore, Margaret E Hellard, ATAHC Study Group

Registry-linked trialOpen access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00192569 (Australian Trial in Acute Hepatitis C), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00192569 phase4completednot on this map

Australian Trial in Acute Hepatitis C

TypeinterventionalSponsorKirby InstituteRan2004 to 2010Enrolled167ConditionsHepatitis CArmsPegylated Interferon alfa 2a, Ribavirin (HIV conifected patients only)
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Joseph S DoyleCentre for Population Health, Burnet Institute, Melbourne, Australia.
Jason GrebelyViral Hepatitis Clinical Research Program, Kirby Institute, UNSW Australia, Sydney, Australia.
Tim SpelmanCentre for Population Health, Burnet Institute, Melbourne, Australia.
Maryam AlaviViral Hepatitis Clinical Research Program, Kirby Institute, UNSW Australia, Sydney, Australia.
Gail V MatthewsViral Hepatitis Clinical Research Program, Kirby Institute, UNSW Australia, Sydney, Australia.
Alexander J ThompsonDepartment of Gastroenterology, St Vincent's Hospital Melbourne, Melbourne, Australia.
Gregory J DoreViral Hepatitis Clinical Research Program, Kirby Institute, UNSW Australia, Sydney, Australia.
Margaret E HellardCentre for Population Health, Burnet Institute, Melbourne, Australia.
ATAHC Study Group
Burnet Institute · AUSt Vincent's Hospital Sydney · AUUniversity of Melbourne · AU

Funding

Treatment of recently acquired hepatitis C virus infectionR01DA015999 · NIDA · UNIVERSITY OF NEW SOUTH WALES · PI DORE, GREGORY JOHN · 2003 to 2014
$3.7M
NIDA NIH HHS R01 DA015999
6 · The paper itself

Abstract

aimDespite effective treatment for recent hepatitis C (HCV) infection, side-effects and adherence concerns limit its use among people who inject drugs (PWID). This study evaluated health-related quality of life (HRQoL) and social functioning following infection and during recent HCV treatment.

methodsThe Australian Trial of Acute Hepatitis C studied the natural history and treatment of recent HCV infection. HRQoL (SF-12v2) and social functioning (Opiate Treatment Index score) were measured over 48 weeks and their impact on treatment uptake, adherence and virological response were assessed.

resultsOf 163 participants, 111 received treatment (HCV n = 74, SVR 55%; HCV/HIV n = 37, SVR 74%). 116 (71%) were male, 124 (76%) ever injected drugs, with 55 (36%) injecting recently and 28/55 (51%) reported needle/syringe sharing. At baseline, median physical and mental HRQoL was 54 units (IQR 46-58) and 46 (35-54) (reference median: 50), respectively, and median social functioning score was 11 units (7-17). Higher social function (<10 vs ≥15) predicted increased treatment uptake (AOR 3.43, 95%CI 1.01-11.6, p = 0.048) and higher SVR (AOR 5.11, 95%CI 1.30-20.15, p = 0.020). After adjustment, treated participants had lower physical (-4.90 units, 95%CI -6.33 to -3.48, p<0.001) and mental HRQoL (-3.7 units, 95%CI -5.55 to -1.86, p<0.001) at on-treatment visits, but HRQoL returned to baseline levels during follow-up.

conclusionsSocial functioning can predict recent HCV treatment uptake and SVR. Efforts to maximise social stability may improve treatment response. Pegylated-interferon treatment is associated with reduced HRQoL on-treatment in an already vulnerable population of PWID that would be better served by interferon-free regimens particularly in treated target at PWID to prevent transmission.

trial registrationClinicalTrials.gov NCT00192569.

Indexed as

AdultAntiviral AgentsAustraliaFemaleHepatitis CHumansInterferon-alphaMaleMiddle AgedNeedle SharingPatient CompliancePatient Outcome AssessmentPolyethylene GlycolsProspective StudiesQuality of LifeRibavirinAntiviral AgentsInterferon-alphaPolyethylene GlycolsRibavirin

Identifiers

PMID27355323
PMCPMC4927167
OpenAlexW2475293456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.